- Companies
- Kenvue
Kenvue Acquisition, Valuation & Financials
Kenvue was acquired by Kimberly-Clark for $49B in November 2025, a 3.2x multiple on $15B of revenue.
Kenvue revenue at acquisition
$15B
Last twelve months · Nov 2025
Kenvue revenue multiple at acquisition
3.2x
EV/Revenue · Nov 2025
Kenvue EBITDA multiple at acquisition
14.3x
EV/EBITDA · Nov 2025
About Kenvue
Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
Founded
2022
HQ
Website
Status
Acquired
Customer focus
B2C
Revenue model
Product sales
Revenue
$15B (Nov 2025)
Valuation
$49B (acquired Nov 2025)
Sectors
Kenvue Acquisition
Kenvue was acquired by Kimberly-Clark for $49B on 3 November 2025.
The acquisition price implies a 3.2x revenue and 14.3x EBITDA multiple on $15B of revenue.
Kimberly-Clark completed its acquisition of Kenvue in November 2026, after agreeing the deal in November 2025. Kenvue shareholders received $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, and the original agreement valued Kenvue at an enterprise value of about $48.7 billion, or about 14.3 times last-twelve-month adjusted EBITDA. Kimberly-Clark shareholders were expected to own about 54% of the combined company and Kenvue holders about 46%. Kimberly-Clark said it expects run-rate synergies of about $2.1 billion, and the combined portfolio includes ten brands with more than $1 billion of sales each, including Huggies, Kleenex, Listerine, Neutrogena and Tylenol. Chairman and chief executive Mike Hsu called the closing a defining moment in the company's 154-year history. Kenvue, the consumer health company spun out of Johnson & Johnson and headquartered in Skillman, New Jersey, was listed on the NYSE until trading stopped on 2 November 2026. Ahead of closing, Kimberly-Clark agreed to divest its European feminine care business to Dilek.
| Acquirer | Date | Type | Price | EV/Revenue | EV/EBITDA |
|---|---|---|---|---|---|
| 3 Nov 2025 | Strategic M&A | $49B | 3.2x | 14.3x |
Sources: kirkland.com, prnewswire.com, personalcareinsights.com, prnewswire.com, prnewswire.com
Kenvue as a Public Company
Kenvue traded as NYS: KVUE before it was taken private. Its acquisition was announced in November 2025. October 2026 is its last month on record as a listed company, with a market cap of $37B and an enterprise value of $44B.
Last-twelve-month revenue was $15B, with EBITDA of $3.7B (24% margin), and the shares traded at 2.9x EV/Revenue and 12.1x EV/EBITDA.
Over the 3 years before that, its market cap grew from $36B in October 2023 to $37B, while revenue grew from $15B to $15B.
Kenvue market cap while listed
Kenvue EV/Revenue (LTM) while listed
| As of | Market cap | Revenue (LTM) | EBITDA (LTM) | EBITDA margin | EV/Revenue | EV/EBITDA |
|---|---|---|---|---|---|---|
| Oct 2026 | $37B | $15B | $3.7B | 24% | 2.9x | 12.1x |
| Oct 2025 | $28B | $15B | $3.4B | 23% | 2.3x | 10.3x |
| Oct 2024 | $44B | $16B | $3.7B | 23% | 3.3x | 14.1x |
| Oct 2023 | $36B | $15B | $3.7B | 24% | 2.8x | 11.7x |
Market cap, enterprise value and last-twelve-month figures are month-end values, up to the last month Kenvue traded.
Kenvue Competitors
Kenvue competitors include listed companies like Reckitt, Hindustan Unilever, Galderma and Estee Lauder, and private ones like A.S. Watson Group and Anastasia Beverly Hills.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $19B | $6.3B | $48B | 3.4x | ||
| Publicly listed | $6.8B | $1.6B | $50B | 6.7x | ||
| Publicly listed | $5.2B | $1.1B | $53B | 8.7x | ||
| Publicly listed | $15B | $1.6B | $40B | 3.0x | ||
| Private | - | - | $23B | - | ||
| Private | $400M | $180M | $3B | 7.5x |
Kenvue Public Comps
Kenvue is no longer listed, but its public comps include Reckitt, Hindustan Unilever, Galderma, Estee Lauder, Haleon, Henkel, Bayer, Ulta Beauty, Church & Dwight and Kao.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $19B | $6.3B | 3.2x | 3.4x | 9.6x | 12.2x | |||
| $6.8B | $1.6B | 7.2x | 6.7x | 30.2x | 29.2x | |||
| $5.2B | $1.1B | 10.5x | 8.7x | 49.2x | 34.1x | |||
| $15B | $1.6B | 3.1x | 3.0x | 29.9x | 17.5x | |||
| $15B | $3.7B | 3.4x | 3.3x | 13.5x | 12.5x | |||
| $23B | $3.8B | 1.7x | 1.6x | 10.3x | 9.2x | |||
| $50B | $3.4B | 2.0x | 1.9x | 29.3x | 9.0x | |||
| $12B | $1.8B | 2.5x | 2.3x | 16.7x | 15.6x | |||
This data is available for Pro users. Sign up to see all Kenvue competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Kenvue
| When was Kenvue founded? | Kenvue was founded in 2022. |
| Where is Kenvue headquartered? | Kenvue is headquartered in New York City, NY, United States. |
| Is Kenvue publicly listed? | No, Kenvue was acquired by Kimberly-Clark in November 2025. |
| Who acquired Kenvue? | Kenvue was acquired by Kimberly-Clark in November 2025. |
| How much was Kenvue acquired for? | Kenvue was acquired for $49B in November 2025, a 3.2x revenue multiple. |
| Which companies are comparable to Kenvue? | Companies comparable to Kenvue include Reckitt, Hindustan Unilever, Galderma, Estee Lauder, A.S. Watson Group and Anastasia Beverly Hills. |
| What was Kenvue's market cap before the acquisition? | Kenvue had a market cap of $37B in October 2026, its last month on record as a listed company, trading at 2.9x EV/Revenue. |
| What was Kenvue's revenue as a public company? | Kenvue's last reported twelve-month revenue was $15B (October 2026), with EBITDA of $3.7B. |
See companies similar to Kenvue
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




